Cardinal Health, Inc.
NYSE•CAH
CEO: Mr. Jason M. Hollar
Sector: Healthcare
Industry: Medical - Distribution
Listing Date: 1983-08-04
Cardinal Health, Inc. operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. It distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products, as well as medical supplies. The company also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; offers pharmacy management services to hospitals; operates pharmacies, including pharmacies in community health centers; and repackages generic pharmaceuticals and over-the-counter healthcare products. In addition, it manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compression solution, incontinence, nutritional delivery, and wound care products; single-use surgical drapes, gowns, and apparel products; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. Further, the company distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. Additionally, it manufactures, prepares, delivers, and distributes radiopharmaceuticals and related treatments; and optimizes direct shipments through integrated technology solutions. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
Contact Information
Market Cap
$45.94B
P/E (TTM)
29.4
28.4
Dividend Yield
1.0%
52W High
$233.60
52W Low
$137.75
52W Range
Rank17Top 4.2%
6.4
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2026 Data
Revenue
$60.94B+0.00%
4-Quarter Trend
EPS
$1.69+0.00%
4-Quarter Trend
FCF
$1.68B+0.00%
4-Quarter Trend
2026 Q2 Earnings Highlights
Key Highlights
Revenue and Earnings Growth Total revenue reached $129.6 B USD for six months, increasing 21 percent; GAAP operating earnings grew 23 percent.
Non-GAAP Earnings Surge Non-GAAP operating earnings increased 38 percent to $1.734 B USD for six months, driven by recent acquisitions.
Strong EPS Performance Six-month GAAP diluted EPS grew 15 percent to $3.85 USD; Non-GAAP diluted EPS rose 36 percent to $5.18 USD.
Pharma Segment Profitability Pharma segment profit increased 28 percent to $1.354 B USD for six months, boosted by MSO acquisitions.
Risk Factors
Opioid Litigation Exposure $4.3 B USD accrued for opioid settlements; payments totaling $403 M USD made during the six months period.
Acquisition Integration Uncertainty Solaris Health acquisition success depends on retaining providers and managing complex MSO platform alignment risks.
Tariff Impact Uncertainty Tariffs impose substantial additional sourcing costs; mitigation efforts may not fully offset potential negative financial impacts.
Increased Interest Expense Interest expense rose significantly to $168 M USD for six months due to debt financing for recent acquisitions.
Outlook
Solaris Health Integration Focus Integrating Solaris Health, a urology MSO acquired for $1.9 B USD, is key for Pharma segment growth strategy.
Capital Deployment Activities Deployed $750 M USD for share repurchases and paid $251 M USD in dividends during the six months period.
Managing Tax Contingency Evaluating IRS proposed adjustment potentially creating $160 M USD federal income tax liability plus interest.
Liquidity Position Maintained Maintained compliance with net leverage ratio covenant of 3.75-to-1; ample liquidity via credit facilities available.
Peer Comparison
Revenue (TTM)
$325.78B
$250.55B
$137.20B
Gross Margin (Latest Quarter)
90.5%
89.3%
82.5%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| COR | $59.14B | 36.3 | 101.4% | 10.1% |
| BDX | $54.09B | 24.2 | 6.9% | 35.6% |
| ARGX | $48.49B | 42.6 | 16.8% | 1.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
0.4%
Moderate Growth
4Q Net Income CAGR
18.6%
Profitability Improved
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:May 7, 2026
EPS:$2.80
|Revenue:$61.91B
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data